julio del 2012 Dr. J. David Jentsch is the recipient of the 2011 Jacob P. Waletzky Memorial Award for Innovative Research in Drug Addiction and Alcoholism. Dr. Jentsch and colleagues at the University of California, Los Angeles, are studying genetic and neurochemical factors that influence individual differences in inhibitory control.
julio del 2012 NIDA researchers working with human subjects now have a new resource at their fingertips: the PhenX Toolkit’s new Substance Abuse and Addiction (SAA) Collection. The Toolkit is designed to provide standardized measures, vetted and approved by the field, to help researchers compare and combine data from multiple studies.
NIDA-supported research suggests that glucocorticoid receptor levels during early brain development affect the hard wiring of neural circuits that shape an individual’s basic emotional makeup. In mice, overexpression of the glucocorticoid gene in the first weeks after birth increased anxiety and response to cocaine in adulthood. These findings may help researchers understand the genetic background and the developmental trajectory of addiction.
A meta-analysis of 13 genome-wide association studies of African Americans’ smoking patterns confirms the significance of genetic variation in region 15q25.1. The analysis also tentatively implicates several genome locations that have not previously been associated with smoking behaviors.
One of NIDA’s goals is to try to understand the individual differences that contribute to whether or not someone who takes a drug will become addicted to it. Dr. Rutter’s research focuses on three types of differences: Environmental, developmental, and genetic and epigenetic.
Two recent studies suggest that genotyping may enable clinicians to base therapies on individual patients’ potential responsiveness to opioid drugs’ therapeutic effects and vulnerability to their harmful effects.